Ravidasvir

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]

Ravidasvir
Clinical data
Other namesPPI-668
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC42H50N8O6
Molar mass762.912 g·mol−1
3D model (JSmol)

Preliminary clinical trial results were announced in Nov 2015.[2]. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[3]. These trials were supported by the Drugs for Neglected Diseases initiative and funded by the charity Médecins Sans Frontières.

See also

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.